Journal Description
Société Internationale d’Urologie Journal
Société Internationale d’Urologie Journal
(SIUJ) is an international, peer-reviewed, open access journal that covers all aspects of urology and related fields. The journal is owned by the Société Internationale d’Urologie (SIU) and is published bimonthly online by MDPI (since Volume 5, Issue 1 - 2024).
- Open Access— free for readers and authors (diamond open access), with article processing charges (APC) paid by the Société Internationale d’Urologie.
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 39.9 days after submission; acceptance to publication is undertaken in 50.3 days (median values for papers published in this journal in the first half of 2025).
- Recognition of Reviewers: APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.
subject
Imprint Information
Open Access
ISSN: 2563-6499
Latest Articles
Navigating the Future of Robotic Urological Surgery: The Hinotori System Joins the Expanding Armamentarium. Comment on Ong et al. Early Clinical Outcomes of the Novel Hinotori Robotic System in Urological Surgery—A Review of Existing Literature. Soc. Int. Urol. J. 2025, 6, 56
Soc. Int. Urol. J. 2025, 6(4), 58; https://doi.org/10.3390/siuj6040058 - 21 Aug 2025
Abstract
Over the past two decades, robotic-assisted surgery has revolutionized the field of urology, offering remarkable advancements in surgical precision, reduced perioperative morbidity, and enhanced postoperative recovery [...]
Full article
Open AccessEditorial
Pathways for Innovation in Urology
by
Peter C. Black
Soc. Int. Urol. J. 2025, 6(4), 57; https://doi.org/10.3390/siuj6040057 - 20 Aug 2025
Abstract
The pages of this month’s Société Internationale d’Urologie Journal (SIUJ) feature important contributions addressing the clinical implementation of innovation and technology in Urology [...]
Full article
Open AccessReview
Early Clinical Outcomes of the Novel Hinotori Robotic System in Urological Surgery—A Review of Existing Literature
by
Simone Meiqi Ong, Hong Min Peng, Wei Zheng So and Ho Yee Tiong
Soc. Int. Urol. J. 2025, 6(4), 56; https://doi.org/10.3390/siuj6040056 - 19 Aug 2025
Abstract
►▼
Show Figures
Robotic-assisted surgery has gradually established its role in uro-oncological cases that demand a high level of precision, optimising surgeon ergonomics and decreasing fatigue whilst maintaining optimal clinical outcomes. With the novel Hinotori surgical robot (Medicaroid Corporation (Kobe, Hyogo, Japan)) launched in Japan back
[...] Read more.
Robotic-assisted surgery has gradually established its role in uro-oncological cases that demand a high level of precision, optimising surgeon ergonomics and decreasing fatigue whilst maintaining optimal clinical outcomes. With the novel Hinotori surgical robot (Medicaroid Corporation (Kobe, Hyogo, Japan)) launched in Japan back in 2019, it has now demonstrated its use case across various clinical series of different surgeries. We sought to narratively synthesise the initial feasibility of the Hinotori robotic system in urology. A systematic, comprehensive literature search was conducted across various databases from September 2024 to October 2024. Relevant keywords within the scope of this study were generated for a more accurate search. After exclusion and removal of duplicates, a total of nine articles were included for review. Among the included studies, one study reported data solely on radical prostatectomy for prostate cancer, two studies reported on robotic-assisted nephroureterectomy for renal tumours, two studies reported on partial nephrectomy performed for renal masses, two studies reported on radical nephrectomy carried out for renal malignancies and one study reported on robotic-assisted adrenalectomy for adrenal cancer. Lastly, one study collectively reported on outcomes pertaining to partial nephrectomy, partial nephrectomy, vesicourethral anastomosis and pelvic lymph node dissection in a porcine model, as well as partial nephrectomy, radical prostatectomy and pelvic lymph node dissection in cadavers. The current literature supports its non-inferiority to the well-established Da Vinci system, with no major drawbacks or concerns identified when comparing parameters such as intraoperative time, estimated blood loss (EBL), perioperative events (transfusions, conversion to open surgery), length of hospital stay and major postoperative complications. Future studies involving larger cohorts and more complex surgical cases are essential to further evaluate the efficacy and safety of the Hinotori system. The new Hinotori robotic system offers unique three-dimensional features as a non-inferior robotic platform alternative that has proven clinically safe thus far in its use. Larger scale studies and randomised trials are eagerly awaited to assess and validate more holistically its clinical utility.
Full article

Figure 1
Open AccessArticle
The “Footprint” Sign in Voiding Cystourethrography Indicates Poor Renal Function in Vesicoureteral Reflux: Is It a Pop-Off Mechanism?
by
Hooman Kamran, Negar Mohammadi Ganjaroudi, Nooshin Tafazoli, Mehrzad Mehdizadeh and Abdol-Mohammad Kajbafzadeh
Soc. Int. Urol. J. 2025, 6(4), 55; https://doi.org/10.3390/siuj6040055 - 19 Aug 2025
Abstract
►▼
Show Figures
Background/Objectives: To assess the “footprint” sign in voiding cystourethrogram (VCUG) for its diagnostic and prognostic significance in indicating a “pop-off” mechanism that may reduce pressure on the contralateral kidney. Methods: A retrospective analysis included patients with a “footprint” sign or high-grade vesicoureteral reflux
[...] Read more.
Background/Objectives: To assess the “footprint” sign in voiding cystourethrogram (VCUG) for its diagnostic and prognostic significance in indicating a “pop-off” mechanism that may reduce pressure on the contralateral kidney. Methods: A retrospective analysis included patients with a “footprint” sign or high-grade vesicoureteral reflux (VUR) in VCUG. They were categorized into two groups: those with (Group A) and those without (Group B) the “footprint” sign. Results: Among 55 patients (median age 18 months), 18 exhibited the “footprint” sign. Group A had predominantly male patients. Bilateral VUR was less common in Group A (38.9%) compared to Group B (51.4%), though not statistically significant (p-value: 0.385). The “footprint” sign was predominantly associated with the left side (77.8% in Group A). The median differential renal function (DRF) was significantly lower in kidneys with the “footprint” sign (11.5%) compared to those without (44.5%, p-value < 0.001). All patients with a DRF under 20% exhibited the “footprint” sign. Conclusions: The “footprint” sign correlates with poor renal function, suggesting a potential pop-off mechanism protecting the contralateral kidney. Management should prioritize the contralateral kidney with normal function. The “footprint” sign alone in VCUG may suffice to indicate compromised renal function, negating the need for further ipsilateral kidney assessment.
Full article

Figure 1
Open AccessArticle
First Multi-Center, Real-World Study on the Temporary Implantable Nitinol Device (iTIND) for the Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction
by
Roberto Castellucci, Silvia Secco, Alberto Olivero, Feras Al Jaafari, Sinan Khadhouri, Alessio Faieta, Cosimo De Nunzio, Riccardo Lombardo, Simone Morselli, Dean Elterman and Luca Cindolo
Soc. Int. Urol. J. 2025, 6(4), 54; https://doi.org/10.3390/siuj6040054 - 13 Aug 2025
Abstract
Background/Objectives: Lower urinary tract symptoms (LUTSs) due to benign prostatic obstruction (BPO) represent a common condition affecting aging men. Transurethral resection of the prostate represents the gold standard surgical treatment but is not without complications such as retrograde ejaculation, bleeding and urinary retention.
[...] Read more.
Background/Objectives: Lower urinary tract symptoms (LUTSs) due to benign prostatic obstruction (BPO) represent a common condition affecting aging men. Transurethral resection of the prostate represents the gold standard surgical treatment but is not without complications such as retrograde ejaculation, bleeding and urinary retention. The temporary implantable nitinol device (iTIND) is considered a minimally invasive surgical technique, designed to treat LUTS while preserving erectile and ejaculatory function. Herein we report the results of a multi-center, real-world assessment of the iTIND procedure. Methods: Data from five international centers treating LUTS with the iTIND device were collected. We recorded changes through an International Prostatic Symptom Score (IPSS) questionnaire with Quality of Life (QoL), International Index of Erectile Function (IIEF5) questionnaire, antegrade ejaculatory function, maximum flow (QMax), post voiding residual volume (PVR) and freedom from repeat intervention. Results: A total of 74 subjects were enrolled; median follow-up was 12 months. IPSS and QoL changed from a median of 23 and 4 points at baseline to 11 and 2 points, respectively, at the last follow-up. A mean improvement in Qmax and PVR from 9 mL/s and 56 mL at baseline to 13 mL/s and 40 mL was noticed at the last follow-up. Total median operative time was 10 min, and the median time of iTIND indwell time was 7 days. The median device removal time was 5 min. There were no changes in IIEF5 scores and antegrade ejaculation rate. No intraoperative complications were reported, and non-serious postoperative complications occurred in six patients (two urinary retention, two mild haematuria, two urinary tract infection). Finally, four patients underwent reoperation during the follow-up period. All procedures were performed as outpatient day cases. Conclusions: Our results confirms that treatment with the iTIND is effective and safe in terms of improving urinary symptoms and quality of life without impacting sexual function. Longer follow-up is required to better define the durability of this minimally invasive procedure.
Full article
Open AccessArticle
Artificial Intelligence in Urology—A Survey of Urology Healthcare Providers
by
Yam Ting Ho, Rizal Rian Dhalas, Muhammad Zohair, Subrata Deb, Mohammed Shoaib, Sandra Elmer, A. H. M. Imrul Tareq, Tauheed Fareed, Nahid Rahman Zico, Agus Rizal Ardy Hariandy Hamid, Isaac A. Thangasamy and Jeremy Y. C. Teoh
Soc. Int. Urol. J. 2025, 6(4), 53; https://doi.org/10.3390/siuj6040053 - 12 Aug 2025
Cited by 1
Abstract
►▼
Show Figures
Background/Objectives: Artificial intelligence (AI) has been utilised in urological conditions such as urolithiasis, urogynaecology and uro-oncology. The aim of this study is to examine the attitudes and beliefs about AI technology amongst urology healthcare providers. Methods: A structured online questionnaire, created
[...] Read more.
Background/Objectives: Artificial intelligence (AI) has been utilised in urological conditions such as urolithiasis, urogynaecology and uro-oncology. The aim of this study is to examine the attitudes and beliefs about AI technology amongst urology healthcare providers. Methods: A structured online questionnaire, created from a modified Delphi method with a panel of urologists and urology surgical trainees, was delivered through the Urological Asia Association’s annual congress. The questionnaire, with 25 items of mixed type responses (five-point Likert scale, nominal-polytomous and open-ended), acquired data regarding demographics, perception and attitudes towards general usage of AI in urological care. Results: A total of 464 respondents from 47 different countries were collected. The results showed that 83.4% of participants believed AI will improve efficiency and 18.8% believed they are knowledgeable in AI technology, with ordinal logistic regression showing both urology specialists and trainees are more likely to agree to these responses. Overall, 51.5% believed AI adoption will not replace clinical practice, and regression analysis found those with previous AI training are more likely to agree to this response. We found AI is commonly used in research, patient education and administrative tasks and identified key enablers as regulatory approval, AI clinical effectiveness and access to AI training. Conclusions: Overall attitudes and beliefs towards the use of AI in urology is positive and encouraging. AI training and education and regulatory reform needs to be addressed to allow integration of AI into clinical practice. A limitation of the study lies in its generalisability to global settings due to the demographics of the respondents.
Full article

Figure 1
Open AccessArticle
Trial of Void at Home After Green Light Laser Photosensitive Vaporisation of the Prostate: A Proof of Concept
by
Arjun Guduguntla, Saad Fahd, Andrew Xu, Lauren Chandler, Ken Chow and Dennis Gyomber
Soc. Int. Urol. J. 2025, 6(4), 52; https://doi.org/10.3390/siuj6040052 - 12 Aug 2025
Abstract
►▼
Show Figures
Background/Objectives: Green light laser photosensitive vaporisation of the prostate (GLL-PVP) is a common procedure for bladder outlet obstruction, with a low incidence of post-operative bleeding. At Northern Health, postoperative management involved limited bladder washout with two bags of 2 L saline, spigotting,
[...] Read more.
Background/Objectives: Green light laser photosensitive vaporisation of the prostate (GLL-PVP) is a common procedure for bladder outlet obstruction, with a low incidence of post-operative bleeding. At Northern Health, postoperative management involved limited bladder washout with two bags of 2 L saline, spigotting, and undergoing a trial of void (TOV) the next morning. A new model of care was commenced in which patients were discharged after the two bags of washout, and the TOV occurred at home through the Hospital in the Home service. The aim of this study was to audit patient outcomes, patient satisfaction, and health service benefits of this novel program. Methods: Patients assigned to the program between March 2023 and June 2024 were analysed. Catheter removal occurred the morning after surgery, and the decision on the success of the TOV was made following an afternoon review. Results: A total of 93.3% (28/30) patients passed their TOV at home. There were no readmissions in the first 48 h postoperation, with only three emergency department (ED) presentations in this time. On a five-point rating scale, 25/25 questionnaire respondents were happy with their care, 20/25 rated the service as very good, and 5/25 rated the service as good. An extra AUD 3377.56 in revenue was generated per patient from the freed inpatient beds, which correlated to a net revenue of AUD 83,016.83 generated over the study period. Conclusions: At-home TOV after GLL-PVP is safe and feasible. There is high patient satisfaction and significant benefits to the healthcare system. This framework can additionally be adopted after other urological surgeries.
Full article

Figure 1
Open AccessCommentary
PSMA PET in Favourable Intermediate-Risk Prostate Cancer? Gold Mine or Money Pit
by
Weiwei Shi, Jianliang Liu, Nathan Lawrentschuk and Marlon Perera
Soc. Int. Urol. J. 2025, 6(4), 51; https://doi.org/10.3390/siuj6040051 - 12 Aug 2025
Abstract
Background/Objectives: Since the proPSMA trial, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scan has primarily replaced conventional imaging for staging newly diagnosed prostate cancer. The objective of this commentary is to summarise the existing literature on the role of PSMA PET
[...] Read more.
Background/Objectives: Since the proPSMA trial, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scan has primarily replaced conventional imaging for staging newly diagnosed prostate cancer. The objective of this commentary is to summarise the existing literature on the role of PSMA PET in staging favourable intermediate-risk prostate cancer. Methods: A literature search was conducted on Embase and Ovid MEDLINE, and three retrospective cohort studies were identified. Results: Overall, these studies demonstrated a low prevalence of nodal and distant metastases, as well as modest diagnostic performance of PSMA positron emission tomography-computed tomography (PET-CT) in this patient group. Additionally, PSMA PET did not significantly outperform existing nomograms in predicting lymph node involvement. Conclusions: Given its limited sensitivity, low yield, and cost, the routine use of PSMA PET-CT in favourable intermediate-risk prostate cancer patients is not recommended. Further prospective studies and cost-effectiveness analyses are warranted to clarify its role in this population.
Full article
Open AccessArticle
Intraurethral Steroid and Clean Intermittent Self-Dilatation for Lichen Sclerosus Proven Urethral Stricture Disease—A Retrospective Cohort Study
by
Alex Buckby, Ramesh Shanmugasundaram and Arman Kahokehr
Soc. Int. Urol. J. 2025, 6(4), 50; https://doi.org/10.3390/siuj6040050 - 12 Aug 2025
Abstract
►▼
Show Figures
Background/Objectives: Lichen sclerosus is a chronic lymphocyte-mediated inflammatory disorder with a predilection for the anogenital region. It is a common cause of urethral stricture disease in males. The gold standard treatment is considered to be surgical reconstruction; however, there are many patients who
[...] Read more.
Background/Objectives: Lichen sclerosus is a chronic lymphocyte-mediated inflammatory disorder with a predilection for the anogenital region. It is a common cause of urethral stricture disease in males. The gold standard treatment is considered to be surgical reconstruction; however, there are many patients who are not suitable or not willing to undergo surgery. Cutaneous lichen sclerosus restricted to the foreskin, prepuce or glans is often response to topical corticosteroids; however, the use of intraurethral corticosteroids for urethral involvement has limited research. Methods: We conducted a retrospective cohort study on 18 patients with histologically confirmed lichen sclerosus and associated urethral stricture disease. They were treated with clean intermittent self catheterisation using a hydrophilic catheter coated with 0.05% betamethasone ointment. International Prostate Symptom Score with Quality of Life scores were measured prior to treatment and at follow-up intervals. Results: There was significant improvement in International Prostate Symptom Score and Quality of Life scores at 3 months, 12 months and 24 months, with only 1 patient ceasing treatment due to intolerance. One patient required a single repeat endoscopic dilatation following a period of non-compliance with treatment. Conclusions: Intraurethral corticosteroids with clean-intermittent self-catheterisation is effective and well tolerated for treating lichen sclerosus-associated urethral stricture disease in the short to intermediate term for patients not willing to undergo urethroplasty.
Full article

Figure 1
Open AccessReview
Barriers to Introducing New Transformative Surgical Technology in Australian Healthcare: A Comprehensive Review and Guide
by
Matthew Alberto, Jennifer Xu, Oneel Patel, Damien Bolton and Joseph Ischia
Soc. Int. Urol. J. 2025, 6(4), 49; https://doi.org/10.3390/siuj6040049 - 12 Aug 2025
Cited by 1
Abstract
►▼
Show Figures
Background/Objectives: Introducing new transformative surgical technology involves navigating a complex process from design to implementation, often hindered by various barriers that delay the transition into clinical practice. This review critically examines the barriers, proposes a unified guide for medical device implementation in
[...] Read more.
Background/Objectives: Introducing new transformative surgical technology involves navigating a complex process from design to implementation, often hindered by various barriers that delay the transition into clinical practice. This review critically examines the barriers, proposes a unified guide for medical device implementation in the Australian healthcare system utilising the validated Medtech Innovation Guide, and compares regulatory frameworks in Australia, the United Kingdom, and the United States of America. Methods: We conducted a literature review using MEDLINE and EMBASE with MeSH terms or emtree terms and keywords “new OR novel” AND “surgical device OR medical device OR health technology OR surgical technology OR surgical instrument OR transformative technology OR technological innovation OR technological change” AND “implementation OR adoption OR innovation adoption” AND “surgery OR surgical” AND “Australia”. We also assessed governmental websites (gov.au) and documents as well as the Royal Australasian College of Surgeons (RACS) website, policies, and position statements. Furthermore, Australian medical technology start-up companies were asked for any published roadmaps. Results: Four key stakeholder groups were identified: medical professionals, government, hospitals, and patients/consumers. Barriers include surgeon scepticism, regulatory hurdles (e.g., Australian Register of Therapeutic Goods), hospital clearance processes, and meeting patient expectations. To address these challenges, we propose a five-phase system: surgical device development (phase one), compliance with regulatory processes (phase two), research and experimentation (phase three), finalisation for product launch (phase four), and product launch and assessment (phase five). Conclusions: By following our five-phase guide, innovators may better navigate the complexities of integrating transformative surgical technologies into Australian healthcare. Although there are limitations, this approach is based on the validated Medtech Innovation Guide and may help both experienced and inexperienced practitioners better implement innovative technology; however, real-world validation is required.
Full article

Figure 1
Open AccessComment
Is Micro-Ultrasound Ready to Become the New Standard for Prostate Cancer Diagnosis? Comment on Saitta et al. SIU-ICUD: Comprehensive Imaging in Prostate Cancer—A Focus on MRI and Micro-Ultrasound. Soc. Int. Urol. J. 2025, 6, 39
by
Chi-Fai Ng
Soc. Int. Urol. J. 2025, 6(3), 48; https://doi.org/10.3390/siuj6030048 - 17 Jun 2025
Abstract
Prostate cancer remains one of the most prevalent malignancies among men worldwide, with early and accurate diagnosis being critical for improving outcomes [...]
Full article
Open AccessEditorial
SIU-ICUD: Localized Prostate Cancer
by
Laurence Klotz
Soc. Int. Urol. J. 2025, 6(3), 47; https://doi.org/10.3390/siuj6030047 - 17 Jun 2025
Abstract
The International Consultation on Urologic Diseases (ICUD) is now 45 years old, representing an illustrious tradition [...]
Full article
Open AccessReview
SIU-ICUD: Management of Lymph Node–Positive Prostate Cancer
by
Haitham Shaheen, Mack Roach 3rd and Eman Essam Elsemary
Soc. Int. Urol. J. 2025, 6(3), 46; https://doi.org/10.3390/siuj6030046 - 13 Jun 2025
Cited by 1
Abstract
►▼
Show Figures
Background/Objectives: The management of localized prostate cancer with regional lymph node involvement (N1M0) presents significant clinical challenges. While once considered indicative of systemic disease, improved imaging and evolving treatment paradigms have redefined node-positive disease as potentially curable. This systematic review aims to
[...] Read more.
Background/Objectives: The management of localized prostate cancer with regional lymph node involvement (N1M0) presents significant clinical challenges. While once considered indicative of systemic disease, improved imaging and evolving treatment paradigms have redefined node-positive disease as potentially curable. This systematic review aims to assess current evidence regarding treatment modalities and outcomes for patients with localized N1M0 prostate cancer. Methods: A systematic review was conducted to identify studies evaluating therapeutic strategies for N1M0 prostate cancer. Eligible studies included randomized controlled trials, retrospective analyses, and consensus guidelines. Treatment approaches reviewed included radical prostatectomy (RP) with pelvic lymph node dissection (PLND), whole pelvic radiotherapy (WPRT), prostate-only radiotherapy (PORT), androgen deprivation therapy (ADT), and metastasis-directed therapy (MDT), including stereotactic body radiotherapy (SBRT). Key outcomes included overall survival (OS), biochemical recurrence-free survival (bRFS), disease-free survival (DFS), and treatment-related toxicity. Results: Multimodal approaches—particularly the combination of ADT with WPRT or adjuvant radiotherapy following RP—were associated with improved survival outcomes. Patients with limited nodal burden and undetectable postoperative prostate-specific antigen (PSA) levels derived the most benefit. The use of prostate-specific antigen membrane positron-emission tomography/computed tomography (PSMA PET/CT) enhanced detection and guided MDT in oligorecurrent disease. SBRT, simultaneous integrated boost (SIB), and hypofractionated regimens demonstrated promising efficacy with acceptable toxicity profiles. Conclusions: Node-positive localized prostate cancer is optimally managed with individualized, multidisciplinary strategies. Combining systemic and locoregional treatments improves outcomes in selected patients. Ongoing prospective studies are warranted to refine patient selection, optimize treatment sequencing, and integrate novel imaging and systemic agents.
Full article

Figure 1
Open AccessReview
SIU-ICUD: Germline Genetic Susceptibility to Prostate Cancer: Utility and Clinical Implementation
by
James T. Kearns, Annabelle Ashworth, Elena Castro, Rosalind A. Eeles, Liesel M. FitzGerald, Peter J. Hulick, Stacy Loeb, Christian P. Pavlovich, Timothy R. Rebbeck, Susan T. Vadaparampil, Zhuqing Shi, Huy Tran, Jun Wei, Jianfeng Xu and Brian T. Helfand
Soc. Int. Urol. J. 2025, 6(3), 45; https://doi.org/10.3390/siuj6030045 - 13 Jun 2025
Cited by 1
Abstract
►▼
Show Figures
Background/Objectives: Prostate cancer is the most common cancer among men globally and a leading cause of cancer-related death. Germline genetic evaluation is increasingly recognized as essential for men with high-risk features such as a strong family history or advanced disease. Methods: Comprehensive genetic
[...] Read more.
Background/Objectives: Prostate cancer is the most common cancer among men globally and a leading cause of cancer-related death. Germline genetic evaluation is increasingly recognized as essential for men with high-risk features such as a strong family history or advanced disease. Methods: Comprehensive genetic risk assessment should integrate three components: family history (FH), rare pathogenic mutations (RPMs), and polygenic risk scores (PRS). RPMs in DNA repair genes (e.g., BRCA2, CHEK2, ATM) can inform screening, prognosis, and treatment strategies, particularly for metastatic or aggressive disease. PRS, derived from common genetic variants, provides a personalized and independent measure of prostate cancer risk and may guide decisions on screening intensity and timing. Results: Although PRS cannot yet differentiate between indolent and aggressive cancer, it has the potential to stratify men into low and high-risk categories more effectively than FH or RPMs alone. Knowledge of specific RPMs can influence treatment decisions in clinically advanced prostate cancer. Challenges in clinical implementation include limited provider awareness, underutilization of genetic counseling, and lack of diversity in genomic datasets, which can lead to misdiagnoses. Emerging technologies and digital tools are being developed to streamline genetic testing and counseling. Population-level strategies and tailored screening protocols based on genetic risk are under active investigation. Conclusions: While early evidence suggests high satisfaction with genetic testing among patients, further studies in diverse populations are needed. Integration of germline genetic information into prostate cancer management offers promising avenues for personalized screening, surveillance, and treatment, ultimately aiming to reduce morbidity and mortality.
Full article

Figure 1
Open AccessReview
SIU-ICUD: Epidemiology of Prostate Cancer
by
Bárbara Vieira Lima Aguiar Melão, Kelly R. Pekala, Konstantina Matsoukas, Ola Bratt and Sigrid V. Carlsson
Soc. Int. Urol. J. 2025, 6(3), 44; https://doi.org/10.3390/siuj6030044 - 12 Jun 2025
Cited by 1
Abstract
►▼
Show Figures
Background/Objectives: Prostate cancer (PCa) is the second most common malignancy among men worldwide and a leading cause of cancer-related mortality. In 2022, over 1.4 million new cases were reported globally, with a prevalence exceeding 5 million. Despite its widespread occurrence, the incidence
[...] Read more.
Background/Objectives: Prostate cancer (PCa) is the second most common malignancy among men worldwide and a leading cause of cancer-related mortality. In 2022, over 1.4 million new cases were reported globally, with a prevalence exceeding 5 million. Despite its widespread occurrence, the incidence and mortality of PCa show substantial geographic variation, influenced by factors such as genetic predisposition, healthcare access, lifestyle, and the adoption of screening programs. Regions with high PCa incidence, such as Northern America and Oceania, often have lower mortality rates due to early detection and advanced healthcare infrastructure. Conversely, areas with limited access to medical resources, such as parts of Africa and Latin America, experience higher mortality rates. Methods: This review explores non-modifiable risk factors such as age, family history, and race, emphasizing their role in PCa development and progression. Results: Modifiable factors, including diet, physical activity, alcohol consumption, and smoking, are also addressed, with evidence suggesting their potential in mitigating risk. Emerging data on medications such as 5-alpha reductase inhibitors and statins, as well as dietary supplements such as vitamins D, indicate their potential for chemoprevention, though further research is needed to solidify these findings. Healthcare disparities, especially in low- and middle-income regions, highlight the need for equitable access to diagnostic tools and treatment options. The review underscores the significance of tailored screening approaches, particularly in high-risk populations, to optimize outcomes while minimizing overdiagnosis and overtreatment. Conclusions: The review concludes with recommendations for future research, including the need for standardized screening protocols and the exploration of novel biomarkers for early detection. By synthesizing epidemiological data and current evidence, this review aims to enhance understanding of PCa risk factors, geographic disparities, and preventive strategies, ultimately contributing to improved global PCa management and outcomes.
Full article

Figure 1
Open AccessReview
SIU-ICUD: Advances in Surgical Technique of Robotic Prostatectomy
by
Belén Mora-Garijo and Keith J. Kowalczyk
Soc. Int. Urol. J. 2025, 6(3), 43; https://doi.org/10.3390/siuj6030043 - 11 Jun 2025
Cited by 1
Abstract
►▼
Show Figures
Background/Objectives: Innovations in robotic prostatectomy have transformed a highly morbid operation to a procedure with fewer complications and shorter hospital stays, yet techniques continue to evolve. Our objective is to discuss the most recent advances in robotic prostatectomy techniques designed to minimize morbidity
[...] Read more.
Background/Objectives: Innovations in robotic prostatectomy have transformed a highly morbid operation to a procedure with fewer complications and shorter hospital stays, yet techniques continue to evolve. Our objective is to discuss the most recent advances in robotic prostatectomy techniques designed to minimize morbidity related to urinary incontinence and erectile dysfunction. Methods: This review is adapted from a comprehensive committee chapter on published in the 3rd WUOF/SIU (World Urologic Oncology Federation/Société Internationale d’Urologie) International Consultation on Urologic Diseases on Localized Prostate Cancer. Results: This review article describes both traditional and emerging techniques in robotic prostatectomy techniques and discusses their respective outcomes. Conclusions: Improved understanding of pelvic anatomy has enabled robotic-assisted techniques to preserve key structures and enhance recovery and functional outcomes while preserving oncologic safety
Full article

Figure 1
Open AccessReview
SIU-ICUD: Principles and Outcomes of Focal Therapy in Localized Prostate Cancer
by
Alessandro Marquis, Jonathan Olivier, Tavya G. R. Benjamin, Eric Barret, Giancarlo Marra, Claire Deleuze, Lucas Bento, Kae J. Tay, Hashim U. Ahmed, Mark Emberton, Arnauld Villers, Thomas J. Polascik and Ardeshir R. Rastinehad
Soc. Int. Urol. J. 2025, 6(3), 42; https://doi.org/10.3390/siuj6030042 - 10 Jun 2025
Cited by 1
Abstract
►▼
Show Figures
Background/Objectives: Focal therapy (FT) for prostate cancer (PCa) is an alternative to radical treatments that aims to balance cancer control and quality of life preservation in well-selected patients. Understanding its general principles and outcomes is key for its widespread adoption and proper implementation.
[...] Read more.
Background/Objectives: Focal therapy (FT) for prostate cancer (PCa) is an alternative to radical treatments that aims to balance cancer control and quality of life preservation in well-selected patients. Understanding its general principles and outcomes is key for its widespread adoption and proper implementation. Methods: The International Consultation on Urological Diseases nominated a committee to review the literature on FT for PCa. A comprehensive PubMed search was conducted to identify articles focused on the different aspects of FT, including patient selection, imaging techniques, treatment modalities, cancer control and safety outcomes, integration with other approaches and future perspectives. Results: FT for PCa was introduced in the 1990s with cryotherapy and high-intensity focused ultrasound (HIFU) as pioneering modalities. Though initially guided by transrectal ultrasound (TRUS) and large biopsy templates, FT implementation expanded significantly with the advent of multiparametric magnetic resonance imaging (MRI) and the validation of the index lesion concept. Appropriate patient selection is key for FT and relies on prostate-specific antigen (PSA) metrics, MRI findings and targeted biopsy information. Multiple energy sources are now available, each with specific technical characteristics. Cancer control rates vary by energy modality, tumor characteristics, and institutional experience, demonstrating comparable outcomes to radical treatments in well-selected patients. The safety profile is excellent, with high rates of urinary continence and sexual function preservation. Post-treatment surveillance integrates PSA measurements, imaging, and histological assessment. Future directions for further FT adoption include the availability of long-term data, protocol standardization and technological improvements to enhance patient selection and treatment planning and delivery. Conclusions: FT is a valuable therapeutic option for selected patients with localized PCa, demonstrating promising oncological outcomes and better functional preservation compared to radical treatments. Understanding its principles and technical aspects is essential for offering comprehensive PCa care.
Full article

Figure 1
Open AccessReview
SIU-ICUD: Localized Prostate Cancer: Pathological Factors That Influence Outcomes and Management
by
Gladell P. Paner, Eva M. Compérat, Samson W. Fine, James G. Kench, Glen Kristiansen, Rajal B. Shah, Steven Christopher Smith, John R. Srigley, Geert J. L. H. van Leenders, Murali Varma, Ming Zhou and Mahul B. Amin
Soc. Int. Urol. J. 2025, 6(3), 41; https://doi.org/10.3390/siuj6030041 - 7 Jun 2025
Cited by 1
Abstract
►▼
Show Figures
Background/Objectives: Pathological factors are integral in the risk stratification and management of localized prostate cancer. In recent years, there has been an upsurge of studies that uncovered novel approaches and have refined prognostic factors for prostate cancer in needle biopsy and radical prostatectomy
[...] Read more.
Background/Objectives: Pathological factors are integral in the risk stratification and management of localized prostate cancer. In recent years, there has been an upsurge of studies that uncovered novel approaches and have refined prognostic factors for prostate cancer in needle biopsy and radical prostatectomy (RP) specimens. Methods: We conducted a review of literature and summarized the significant recent updates on pathological factors for localized prostate cancer. Results: Innovative factors derived from the traditional Gleason grading, such as the extent of Gleason pattern 4 and presence of cribriform pattern are now recognized to significantly improve discrimination of outcome. The components and rules of Gleason grading themselves underwent modifications, and the subsequent prognostic grouping of the different grades (Grade group) have resulted in enhanced stratification of behavior more meaningful in management decision. The approaches for grade reporting in systematic or targeted needle biopsies and in RP with multifocal cancers are also being optimized. Newer tumor growth pattern-based factors such as intraductal carcinoma and atypical intraductal proliferation can have ramifications in management, especially in the background of low to intermediate risk prostate cancers. Gleason grade considerations in the different post-treatment settings and for de novo and residual prostate cancers with varying treatment effects have also been explicated. Likewise, the application of more traditional factors in tumor extent and perineural invasion in biopsy, or positive surgical margin in RP, have also evolved. Conclusions: Some of these newer pathological factors are now officially recommended in standardized pathology reporting protocols and are applied in the management decision for localized prostate cancer.
Full article

Figure 1
Open AccessReview
SIU-ICUD: Prevention of Lethal Prostate Cancer via Modifiable Heart-Healthy Lifestyle Changes, Metrics, and Repurposed Medications
by
Mark A. Moyad, Raj V. Tiwari, Daniel A. Galvão, Dennis R. Taaffe and Robert U. Newton
Soc. Int. Urol. J. 2025, 6(3), 40; https://doi.org/10.3390/siuj6030040 - 7 Jun 2025
Cited by 1
Abstract
Background/Objectives: Primary prevention, germline, familial, or other pre- or post-diagnostic and standard treatment-elevated progression or recurrence risk and mitigating adverse events from systemic treatment are all clinical opportunities to reduce the risk of lethal prostate cancer. This review attempted to provide a
[...] Read more.
Background/Objectives: Primary prevention, germline, familial, or other pre- or post-diagnostic and standard treatment-elevated progression or recurrence risk and mitigating adverse events from systemic treatment are all clinical opportunities to reduce the risk of lethal prostate cancer. This review attempted to provide a practical and realistic consensus via an international committee of experts who, in general, harbor career-long experience in this discipline. Methods: A PubMed review primarily utilizing the latest meta-analyses, systematic reviews, and methodologically robust epidemiologic recent data adjusting for multiple confounding variables was conducted. The goal of this committee was to highlight tangible options for clinicians and patients. Results: Behavioral patterns and metrics known to reduce cardiovascular morbidity, mortality, and all-cause mortality (premature death) appear to prevent numerous lethal common cancers, including prostate cancer. This practical approach allows for the greatest probability of patient success since cardiovascular disease (CVD) is the primary cause of death in men with and without prostate cancer, and a notable source of morbidity and mortality in men with advanced disease due to systemic conventional treatment as well as the inflammatory contribution of cancer itself. Heart-healthy dietary patterns, exercise, healthy weight/waist circumference, eliminating tobacco, minimizing alcohol exposure, and other behaviors to reduce the risk of CVD should be prioritized. CVD-preventive medications, including aspirin, GLP-1 agonists, metformin, statins, etc., should receive attention to improve compliance for those that already qualify for these agents and to increase the probability of enhancing the quality and quantity of life. Dietary supplements do not have favorable data currently to espouse their utilization to prevent lethal prostate cancer but may have an ancillary role in mitigating some adverse effects of treatment. Conclusions: Remarkably, heart-healthy lifestyle changes, metrics, and promising repurposed medications known to reduce cardiovascular events, promote longevity, and improve mental health could simultaneously prevent lethal prostate cancer. This serendipitous association provides clinicians and their patients a higher probability of success, regardless of their prostate cancer pathway or circumstance.
Full article
Open AccessReview
SIU-ICUD: Comprehensive Imaging in Prostate Cancer—A Focus on MRI and Micro-Ultrasound
by
Cesare Saitta, Wayne G. Brisbane, Hannes Cash, Sangeet Ghai, Francesco Giganti, Adam Kinnaird, Daniel Margolis and Giovanni Lughezzani
Soc. Int. Urol. J. 2025, 6(3), 39; https://doi.org/10.3390/siuj6030039 - 7 Jun 2025
Cited by 1
Abstract
►▼
Show Figures
Background/Objectives: The diagnostic approach to prostate cancer (PCa) has evolved from systematic biopsies to imaging-guided strategies that improve detection of clinically significant PCa (csPCa) while reducing overdiagnosis. Multiparametric magnetic resonance imaging (mpMRI) has emerged as the gold standard for pre-biopsy evaluation, while micro-ultrasound
[...] Read more.
Background/Objectives: The diagnostic approach to prostate cancer (PCa) has evolved from systematic biopsies to imaging-guided strategies that improve detection of clinically significant PCa (csPCa) while reducing overdiagnosis. Multiparametric magnetic resonance imaging (mpMRI) has emerged as the gold standard for pre-biopsy evaluation, while micro-ultrasound (MicroUS) offers a promising alternative with real-time imaging capabilities. Methods: We examined the principles, image interpretation frameworks (Prostate Imaging Reporting and Data System (PI-RADS) and Prostate Risk Identification using Micro UltraSound (PRI-MUS)), and clinical applications of mpMRI and MicroUS, comparing their diagnostic accuracy in biopsy-naïve patients, repeat biopsy scenarios, active surveillance, and staging. Results: mpMRI improves csPCa detection, reduces unnecessary biopsies, and enhances risk stratification. Landmark studies such as PRECISION (Prostate Evaluation for Clinically Important Disease: Sampling Using Image Guidance or Not?) and PRIME (Prostate Imaging Using MRI±Contrast Enhancement) confirm its superiority over systematic biopsy. However, mpMRI remains resource-intensive, with limitations in accessibility and interpretation variability. Conversely, MicroUS, with its high-resolution real-time imaging, shows non-inferiority to mpMRI and potential advantages in magnetic resonance imaging (MRI)-ineligible patients. It improves lesion visualization and biopsy targeting, with ongoing trials such as OPTIMUM (Optimization of prostate biopsy—Micro-Ultrasound versus MRI) evaluating its standalone efficacy. Conclusions: mpMRI and MicroUS are complementary modalities in PCa diagnosis. While mpMRI remains the preferred imaging standard, MicroUS offers an alternative, particularly in patients with MRI contraindications. Combining these techniques could enhance diagnostic accuracy, reduce unnecessary interventions, and refine active surveillance strategies. Future research should focus on integrating both modalities into standardized diagnostic pathways for a more individualized approach.
Full article

Figure 1

Journal Menu
► ▼ Journal MenuJournal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
